News

July 27, 2017
Second quarter of 2017:

Bayer: Group performance matches prior year despite declines at Crop Science
Group sales increase by 3.0 percent (Fx & portfolio adj.: plus 1.9 percent) to EUR 12,193 million / EBITDA before special items level with the prior year, at EUR 3,056 million (plus 0.1 percent) / Pharmaceuticals posts strong increase in earnings and margins / Brazil business weighs on Crop Science / Consumer Health encounters difficult market environment in the United States / Significant increase in sales and earnings at Covestro / Net income decreases by 11.3 percent to EUR 1,224 million / Core earnings per share EUR 1.81 (minus 12.6 percent) / Monsanto acquisition on track / Group outlook for 2017 adjusted more

July 21, 2017
Not intended for U.S. and UK Media

Bayer’s Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement more

July 21, 2017
Not intended for U.S. and UK Media

Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma more

News Overview

Bayer Group

Interim Report Q2

On Thursday, July 27, 2017, Werner Baumann and Johannes Dietsch presented the second quarter results of Bayer AG.

more

Advancing Together: Bayer to Acquire Monsanto

The acquisition realizes the joint vision of integrated agricultural offering delivering superior solutions for growers and creates an innovation powerhouse for the next generation of farming.

more

Products

Select product

Themes

Select topic or theme

Organization

Select business area

Countries

Select country

Special Interest

Modern Slavery Act Statement
Calendar
Covestro
Foundations
Information for Patients
Sports

Media

Publications
Social Media
Videos
Apps

Follow Us

Share Price/Index